Identifying metabolic features of colorectal cancer liability using Mendelian randomization.

ALSPAC CCFR CCTS Colorectal cancer Epidemiology GECCO Genetics Mendelian randomization Metabolism NMR UK Biobank

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
09 Nov 2023
Historique:
pubmed: 23 3 2023
medline: 23 3 2023
entrez: 22 3 2023
Statut: epublish

Résumé

Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development. This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.

Sections du résumé

Background UNASSIGNED
Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival.
Methods UNASSIGNED
To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years.
Results UNASSIGNED
The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk.
Conclusions UNASSIGNED
These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development.
Funding UNASSIGNED
This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.

Identifiants

pubmed: 36945480
doi: 10.1101/2023.03.10.23287084
pmc: PMC10029059
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R01 CA067941
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG004438
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG004446
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA154337
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097325
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA067941
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA059045
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00002
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197350
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA076366
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00005
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072520
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA152753
Pays : United States
Organisme : NIH HHS
ID : S10 OD028685
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA048998
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA137088
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA189184
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 CP010200
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA066635
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206110
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242218
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00001
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA081488
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA143237
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201407
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA033619
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA086308
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00003
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207371
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA153323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA042182
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA060987
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA048998
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES013678
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136726
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA152715
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA122839
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182883
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA054281
Pays : United States
Organisme : WHI NIH HHS
ID : 75N92021D00004
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148107
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG018033
Pays : United States

Références

Elife. 2021 May 04;10:
pubmed: 33942721
Genet Epidemiol. 2016 Nov;40(7):597-608
pubmed: 27625185
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
BMC Med. 2022 Jun 13;20(1):210
pubmed: 35692035
Wellcome Open Res. 2019 Mar 14;4:51
pubmed: 31020050
Lancet Oncol. 2021 Jul;22(7):1002-1013
pubmed: 34048685
Oncotarget. 2022 Jan 07;13:61-72
pubmed: 35028011
BMC Med. 2020 Dec 17;18(1):396
pubmed: 33327948
World J Diabetes. 2010 Jul 15;1(3):76-88
pubmed: 21537431
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Molecules. 2020 Aug 28;25(17):
pubmed: 32872164
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Am J Clin Nutr. 2019 Jan 1;109(1):7-16
pubmed: 30596814
Cancer Causes Control. 2015 Feb;26(2):257-268
pubmed: 25488827
Lipids Health Dis. 2018 Nov 14;17(1):255
pubmed: 30428911
Transl Oncol. 2021 Jun;14(6):101043
pubmed: 33751965
Onco Targets Ther. 2019 May 02;12:3339-3347
pubmed: 31118685
Eur J Cancer. 2017 Oct;84:228-238
pubmed: 28829991
Br J Cancer. 2016 Sep 27;115(7):848-57
pubmed: 27560555
Hum Mol Genet. 2022 Nov 28;31(23):4034-4054
pubmed: 35796550
Diabetes. 2022 Feb 1;71(2):329-339
pubmed: 34785567
Metabolites. 2021 May 13;11(5):
pubmed: 34068443
Int J Cancer. 2017 Jun 15;140(12):2701-2708
pubmed: 28340513
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Gut. 2021 Jul;70(7):1325-1334
pubmed: 33632709
Int J Epidemiol. 2003 Feb;32(1):1-22
pubmed: 12689998
Int J Cancer. 2002 May 10;99(2):260-6
pubmed: 11979442
Cancer Res. 2012 Jan 1;72(1):356-64
pubmed: 22080567
Curr Gastroenterol Rep. 2019 Dec 2;21(11):62
pubmed: 31792624
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Int J Epidemiol. 2017 Dec 1;46(6):1985-1998
pubmed: 29040600
JAMA Cardiol. 2020 Jun 1;5(6):694-702
pubmed: 32186652
Elife. 2018 May 30;7:
pubmed: 29846171
J Korean Med Sci. 2000 Dec;15(6):690-5
pubmed: 11194196
BMJ Open. 2022 Jun 22;12(6):e052373
pubmed: 35732386
Cancer Lett. 2014 Apr 1;345(1):17-20
pubmed: 24333717
Nat Genet. 2009 Jan;41(1):56-65
pubmed: 19060906
Nat Commun. 2019 May 14;10(1):2154
pubmed: 31089142
Am J Epidemiol. 2017 Nov 1;186(9):1084-1096
pubmed: 29106475
J Proteome Res. 2009 Oct;8(10):4844-50
pubmed: 19678709
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Am Fam Physician. 2022 Jan 1;105(1):Online
pubmed: 35029948
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
Cancer Epidemiol Biomarkers Prev. 2020 Apr;29(4):860-870
pubmed: 32051193
J Cancer Res Clin Oncol. 2021 Dec;147(12):3591-3599
pubmed: 34490583
PLoS Genet. 2009 Jan;5(1):e1000338
pubmed: 19148276
PLoS One. 2017 Feb 6;12(2):e0170664
pubmed: 28166253
Gastroenterology. 2020 Jan;158(2):418-432
pubmed: 31394083
Ann Surg. 2012 Apr;255(4):720-30
pubmed: 22395091
Oncotarget. 2018 May 15;9(37):24787-24800
pubmed: 29872506
Genome Med. 2012 May 14;4(5):42
pubmed: 22583555
J Nutr Biochem. 2012 Oct;23(10):1302-13
pubmed: 22221675
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
N Engl J Med. 1986 Dec 25;315(26):1634-8
pubmed: 3785334
Clin Chem. 2019 Mar;65(3):363-366
pubmed: 30692117
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
PLoS Med. 2016 Apr 26;13(4):e1002007
pubmed: 27116322
PLoS One. 2012;7(7):e40459
pubmed: 22792336
Gastroenterology. 2022 Oct;163(4):1024-1037.e9
pubmed: 35788345
Eur J Clin Nutr. 2020 Aug;74(8):1132-1148
pubmed: 32029911
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
BMC Med. 2010 Feb 15;8:13
pubmed: 20156336
EBioMedicine. 2023 May;91:104510
pubmed: 37086649
Curr Pharmacol Rep. 2017 Jun;3(3):114-125
pubmed: 28642837
Eur J Epidemiol. 2018 Oct;33(10):947-952
pubmed: 30039250
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):55-62
pubmed: 31668584
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Metabolomics. 2012 Aug;8(4):643-653
pubmed: 22833708
Int J Cancer. 2020 Feb 1;146(3):861-873
pubmed: 31037736
Public Health Nutr. 2015 Dec;18(18):3355-70
pubmed: 25776573
Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1015-1023
pubmed: 30948449
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):995-1010
pubmed: 29941659

Auteurs

Caroline J Bull (CJ)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Translational Health Sciences, Bristol Medical School, University of Bristol, UK.

Emma Hazelwood (E)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Joshua A Bell (JA)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Vanessa Y Tan (VY)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Andrei-Emil Constantinescu (AE)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Maria Carolina Borges (MC)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Danny N Legge (DN)

Translational Health Sciences, Bristol Medical School, University of Bristol, UK.

Kimberly Burrows (K)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Jeroen R Huyghe (JR)

Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sergi Castellví-Bel (S)

Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.

Andrew T Chan (AT)

Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.

Sun-Seog Kweon (SS)

Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea.
Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, Korea.

Loic Le Marchand (LL)

University of Hawaii Cancer Center, Honolulu, Hawaii, USA.

Li Li (L)

Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA.

Iona Cheng (I)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, San Francisco, California, USA.

Rish K Pai (RK)

Department of Pathology and Laboratory Medicine, Mayo Clinic, Arizona, Scottsdale, Arizona, USA.

Jane C Figueiredo (JC)

Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Neil Murphy (N)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.

Marc J Gunter (MJ)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom.

Nicholas J Timpson (NJ)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Emma E Vincent (EE)

MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Translational Health Sciences, Bristol Medical School, University of Bristol, UK.

Classifications MeSH